Difference between revisions of "Venlafaxine-bupropion"

From Psychiatrienet
Jump to: navigation, search
 
(2 intermediate revisions by the same user not shown)
Line 3: Line 3:
 
| to = bupropion  
 
| to = bupropion  
 
| stop =  
 
| stop =  
{{downVenla}}
+
{{stopVenlafaxine}}
 
| start =  
 
| start =  
* '''Day 15:''' start bupropion in a normal dosage of 150 mg/day.
+
* '''Day 9:''' start bupropion in a normal dosage of 150 mg/day.
 
 
 
 
 
}}
 
}}

Latest revision as of 11:43, 4 November 2015

Venlafaxine
Type Antidepressant
Group SNRI
links
Medscape Venlafaxine
PubChem 5656
PubMed Venlafaxine
Kompas (Dutch) Venlafaxine
Wikipedia Venlafaxine
Bupropion
Type Antidepressant
Group other
links
ATC-code N06AX12
Medscape Bupropion
PubChem 444
PubMed Bupropion
Kompas (Dutch) Bupropion
Wikipedia Bupropion

Switch medication from venlafaxine to bupropion.[1] [2]

Nietinrijdenbord.png Stop venlafaxine
  • Before day 1: gradually reduce dosage of venlafaxine to a maximum of 75 mg/ day.
  • Day 1: reduce a dosage of 75 mg/day to 37,5 mg/day.
  • Day 8: stop administration of venlafaxine.
Eenrichtingbord.png Start bupropion
  • Day 9: start bupropion in a normal dosage of 150 mg/day.


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.